07:00 Tue 21 Nov 2017
NetScientific PLC - ProAxsis: Sales Update
("
ProAxsis Announces Sales Acceleration of its CE Marked Active Neutrophil Elastase Immunoassay
Commenting on the news,
The full text of the announcement from ProAxsis can be found below.
# # #
For more information, please contact:
|
Tel: +44 (0)20 3514 1800 |
|
Tel: +44 (0)20 3709 5700 |
|
Tel: +44 (0) 20 7710 7600 |
ProAxsis provides update on commercialisation progress
Date:
Having reached the first anniversary following relocation to its new purpose-built laboratory on the
The ProteaseTag® Active Neutrophil Elastase Immunoassay was registered with a CE Mark in the latter half of 2016, and is becoming increasingly popular with both academic and pharmaceutical company researchers. Kit sales of this immunoassay to date in H2 2017 are already more than triple those recorded in H1 2017. Importantly, whilst new customers continue to initiate first usage of the immunoassay, more than 75% of 2017 customers have returned with follow-up orders. As a result of the increased awareness and requests for the immunoassay, the company announced recently that it has appointed its first distributor,
The company's first point-of-care test, NEATstik®, was recently registered with a CE Mark, and the company maintains a strong R&D pipeline, with further product launches anticipated in the near future. Resultantly, ProAxsis remains on track to surpass
Dr
ProAxsis is part of the
To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com
About
About
ProAxsis is developing a range of products for the capture, detection and measurement of active protease biomarkers of diseases. Its first immunoassay measures neutrophil elastase, a leading indicator of infection and inflammation in patients with Cystic Fibrosis (CF), Chronic Obstructive Pulmonary Disease (COPD) and bronchiectasis, and an important drug target. The rapid and easy-to-use tests being developed by ProAxsis incorporate patented ProteaseTags®; smart molecules which trap an active protease within a complex biological sample and enable a visual readout of its presence. ProteaseTags® provide a unique tool to identify and quantify active protease biomarkers and will assist in the clinical validation of new therapeutics.
ProAxsis is part of the
This information is provided by RNS
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...
FOR OUR FULL DISCLAIMER CLICK HERE